A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) | MicrobiomeTrials
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2023-01-23Est. Completion: 2028-07-31
Enrollment target: 20 participants
Locations
Children's National Medical Center, Washington D.C., District of Columbia, United States
Emory University Hospital, Atlanta, Georgia, United States
Northwestern University Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago - Neonatology, Chicago, Illinois, United States
Riley Hospital for Children, Indianapolis, Indiana, United States
Children's Hospital - New Orleans, New Orleans, Louisiana, United States
Johns Hopkins Pediatric Specialty Clinic, Baltimore, Maryland, United States
C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Primary Children's Hospital, Salt Lake City, Utah, United States
Université Catholique De Louvain And Cliniques St Luc, Brussels, Brussels Capital, Belgium